Mycobacterial genomic DNA from used Xpert MTB/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping by Venter, Rouxjeane et al.
1SCiENTiFiC REPORTS | 7: 14854  | DOI:10.1038/s41598-017-14385-x
www.nature.com/scientificreports
Mycobacterial genomic DNA from 
used Xpert MTB/RIF cartridges can 
be utilised for accurate second-
line genotypic drug susceptibility 
testing and spoligotyping
Rouxjeane Venter1, Brigitta Derendinger1, Margaretha de Vos1, Samantha Pillay1,2, Tanya 
Dolby2, John Simpson2, Natasha Kitchin1, Ashley Ruiters2, Paul D. van Helden1, Robin M. 
Warren1 & Grant Theron1
Xpert MTB/RIF (Xpert) is a widely-used test for tuberculosis (TB) and rifampicin-resistance. Second-line 
drug susceptibility testing (DST), which is recommended by policymakers, typically requires additional 
specimen collection that delays effective treatment initiation. We examined whether cartridge extract 
(CE) from used Xpert TB-positive cartridges was, without downstream DNA extraction or purification, 
suitable for both genotypic DST (MTBDRplus, MTBDRsl), which may permit patients to rapidly receive a 
XDR-TB diagnosis from a single specimen, and spoligotyping, which could facilitate routine genotyping. 
To determine the limit-of-detection and diagnostic accuracy, CEs from dilution series of drug-susceptible 
and -resistant bacilli were tested (MTBDRplus, MTBDRsl). Xpert TB-positive patient sputa CEs (n = 85) 
were tested (56 Xpert-rifampicin-susceptible, MTBDRplus and MTBDRsl; 29 Xpert-rifampicin-resistant, 
MTBDRsl). Spoligotyping was done on CEs from dilution series and patient sputa (n = 10). MTBDRplus 
had high non-valid result rates. MTBDRsl on CEs from dilutions ≥103CFU/ml (CT ≤ 24, >“low” Xpert 
semiquantitation category) was accurate, had low indeterminate rates and, on CE from sputa, highly 
concordant with MTBDRsl isolate results. CE spoligotyping results from dilutions ≥103CFU/ml and sputa 
were correct. MTBDRsl and spoligotyping on CE are thus highly feasible. These findings reduce the need 
for additional specimen collection and culture, for which capacity is limited in high-burden countries, 
and have implications for diagnostic laboratories and TB molecular epidemiology.
Of the 10.4 million individuals with active tuberculosis (TB) in 2015, 580 000 were rifampicin (RIF) resistant or 
multidrug-resistant (MDR), defined as resistance to isoniazid (INH) and RIF1. Only ~20% of MDR-TB cases were 
diagnosed and started on treatment, and only half started on treatment were cured1. Extensively drug-resistant 
(XDR)-TB, which is MDR with resistance to a fluoroquinolone (FQ) and a second-line injectable drug (SLID) 
comprises 10% of MDR-TB cases, yet is even more underdiagnosed than MDR-TB, very costly to treat, and rep-
resents an emerging public health emergency2–6.
Xpert MTB/RIF (Xpert) (Cepheid, United States) is a Food and Drug Administration and World Health 
Organization (WHO)-endorsed nucleic acid amplification test (NAAT) that rapidly detects Mycobacterium 
tuberculosis complex-DNA and RIF-resistance directly from sputa7–9. Over 25 million Xpert MTB/RIF cartridges 
have been consumed and over 30 000 test modules are installed worldwide10. The WHO and several national 
programmes recommend that if Xpert detects resistance, an additional sputum is collected for further drug 
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susceptibility testing (DST) using line probe assays (LPAs), such as MTBDRplus (RIF and INH) and MTBDRsl 
(FQs and SLIDs), or phenotypic testing1,9,11,12.
Patients, however, often do not rapidly return to the clinic to give another sputum or receive DST results. For 
example, a study in South Africa found that, even after MTBDRplus roll-out, time-to-treatment since initial diag-
nosis was unacceptably long (~55 days), and that this was partly due to challenges with patient loss-to-follow-up13. 
Furthermore, many patients do not produce sufficient sputum of adequate quality, especially in settings with high 
rates of HIV14–17.
MTBDRplus and MTBDRsl have suboptimal sensitivity on specimens, and culture is often required prior to 
DNA extraction and further genotypic testing. Not only can this cause diagnostic delay, but many high burden 
countries lack the necessary biosafety and laboratory infrastructure for mycobacterial culture and DNA extrac-
tion18–21. Furthermore, culture can result in the loss of potentially clinically-meaningful resistance22. There is 
hence a need to reduce delays in the diagnosis of drug-resistant TB and use rapid methods that minimise reliance 
on culture through the direct testing of specimens23.
Poor adherence to diagnostic algorithms using MTBDRplus and MTBDRsl has been reported5,24,25. For exam-
ple, in South Africa, 34% of Xpert RIF-resistant patients failed to receive MTBDRplus and, of those confirmed 
to have MDR-TB, 28% did not receive second-line DST with MTBDRsl – despite both LPAs being mandated by 
the national programme21. Novel approaches to reduce this gap in the TB care cascade, which is worsened by 
the requirement for extra patient visits and additional specimen collection, is a major research priority26,27. If 
TB-testing and first- and second-line DST were possible on the first available specimen, fewer patients would 
potentially be lost and patients could be diagnosed earlier. This could result in earlier effective treatment initia-
tion, fewer patient- and health systems-costs, and better long-term clinical outcomes.
We therefore conducted a proof-of-concept evaluation on whether M. tuberculosis-complex genomic DNA 
in the PCR-reaction mix from used Xpert cartridges (cartridge extract; CE) - that would otherwise be discarded 
- was detectable in an accurate manner using MTBDRplus and MTBDRsl. The feasibility of genotyping on CE 
by spoligotyping was also tested as this would potentially be useful for research laboratories and programmes 
seeking to implement routine strain surveillance. We explored the feasibility of Sanger sequencing on CE, as this 
may be useful for additional genotypic DST. Critically, we evaluated CE for all tests without additional down-
stream DNA extraction or purification, as not only would extraction require equipment not readily available in 
routine diagnostic laboratories in high burden settings, but it would complicate laboratory workflows and reduce 
the attractiveness of our approach. If the CE approach was feasible, it would mean that many laboratories would 
already have instrumentation available for mycobacterial genomic DNA extraction in the form of GeneXpert10 
and not need to procure new equipment.
Material and Methods
Ethics statement. Methods and protocols were carried out in accordance with relevant guidelines and 
regulations. The study was approved by the Health Research Ethics Committee of Stellenbosch University 
(N09/11/296) and the City of Cape Town (#10570). Permission was granted to use anonymised residual speci-
mens collected as part of routine diagnostic practice and thus informed consent was waived.
Xpert MTB/RIF on dilution series of drug-susceptible- and drug-resistant bacilli. A triplicate ten-
fold dilution series was made using phenotypically-confirmed drug-susceptible (DS)-TB, MDR-TB and XDR-TB 
clinical isolates (0–106 CFU/ml) in phosphate buffer (33 mM Na2HPO4, 33 mM KH2PO4; pH 6.8) with 0.025% 
Tween80 (Sigma-Aldrich, United States). Colony counts were done by plating on 7H11 Middlebrook agar (BD 
Biosciences, United States). Dilutions containing bacilli (1 ml aliquots) were tested by Xpert (54 in total: six dilu-
tions ranging from 101–106 CFU/ml in triplicate for three strains and hence 18 dilutions each for the DS, MDR, 
and XDR strains) as well as 0 CFU/ml controls in triplicate, according to the manufacturer’s instructions9. Used 
cartridges were stored at 4 °C prior to CE extraction within 24 h and freezing of the CE at −20 °C.
Xpert MTB/RIF on clinical specimens. Used Xpert-TB-positive cartridges done on sputa from people 
with symptoms suggestive of TB tested as part of the South African national TB diagnostic algorithm were col-
lected between February 2016 and November 2016 from the National Health Laboratory Services (NHLS), a 
South African National Accreditation System-accredited, quality-assured diagnostics laboratory in Cape Town, 
South Africa11. Cartridges were stored at 4 °C prior to CE extraction within 5 days. Fifty-six Xpert TB-positive, 
RIF-susceptible cartridges and 29 Xpert-TB-positve RIF-resistant cartridges were collected. When the NHLS 
did a MGIT 960 liquid culture on sputum from RIF-resistant patients, we collected the isolate [20/29 (69%) had 
available isolates]. Isolates were not available from Xpert TB-positive, RIF-susceptible specimens as culture is not 
routinely done in these patients11,28.
Recovery of mycobacterial genomic DNA from used Xpert MTB/RIF cartridges. The transparent 
diamond-shaped reaction chamber on the back of the cartridge was punctured with a sterile fixed-needle insulin 
syringe (1 ml; 29 G) (Fig. 1) in a biosafety level 2 cabinet. The full CE volume, typically ~15 µl, was withdrawn and 
stored in sterile, safe-lock micro-centrifuge tubes at −20 °C prior to analysis. Each cartridge and the surrounding sur-
face was wiped down thoroughly with 1% sodium hypochlorite and 70% EtOH before and after extraction and UV 
sterilization was done after each batch of extraction. Used needles were discarded in a sharps container containing 
1% sodium hypochlorite. Before and after each cartridge extraction session, hood surface area was decontaminated 
with sodium hypochlorite and EtOH and UV sterilised. No DNA extraction or purification steps were done on CE.
Line probe assays on cartridge extract. MTBDRplus and MTBDRsl (both version 2.0) were done 
according to the manufacturer’s instructions29,30 except for Xpert TB-positive, RIF-susceptible clinical specimens 
CE (n = 56), 7.5 µl CE was used as imput volume into MTBDRplus and MTBDRsl. For the Xpert TB-positive, 
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RIF-resistant clinical specimen CEs (n = 29) and the dilution series, 5 µl (the recommended imput volume) CE 
was used in order to have enough CE remaining for Sanger sequencing. MTBDRplus and MTBDRsl results were 
reported as susceptible or resistant (RIF and INH for MTBDRplus; FQ and SLID for MTBDRsl), indeterminate 
[M. tuberculosis complex DNA-positive (reported by the test as TUB-positive) but no gene loci control bands] or 
TUB-band negative. LPA strips were read by two independent, experienced readers blinded to each other’s calls 
and Xpert results (and, for dilution series, the strain used).
Spoligotyping on cartridge extract. Spoligotyping was done as described31,32 on 2 µl CE from the 
MDR-TB dilution series. A set of Xpert TB-positive, RIF-susceptible cartridges (n = 10) done on specimens and 
separate from those used for genotypic DST on CE were collected with paired culture isolates from an ongo-
ing research study. To determine whether the correct spoligotype was obtained from CE, crude DNA extracted 
through heat inactivation from the corresponding culture isolates was spoligotyped. SITVIT was used to identify 
strain families33.
Targeted Sanger sequencing on cartridge extract. For dilution series, PCR clean-up and Sanger 
sequencing on 5 µl CE was done by the Stellenbosch University Central Analytical Facility using primers over-
lapping with LPA-binding sites (Supplementary Table 1). The gyrA and rrs regions in the DS-TB and XDR-TB 
strains were sequenced.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Patient characteristics. A summary of the patient demographic and clinical data is in Table 1. For 
Xpert TB-positive, RIF-susceptible patients the median age (IQR) was 40 (31–49) years and for RIF-resistant specimens 
was 35 (23–42) years. 37/55 (67%) of RIF-susceptible patients and 12/20 (60%) of RIF-resistant patients were male.
Feasibility and diagnostic accuracy of MTBDRplus and MTBDRsl on dilution series Xpert 
TB-positive cartridge extract. Xpert detected M. tuberculosis-complex DNA in all dilutions ≥102 CFU/
ml and correctly identified RIF-susceptibility and -resistance (Fig. 2). MTBDRplus showed poor overall sensitivity 
for M. tuberculosis-complex DNA [22% (12/54) TUB-band-positive] in CE from Xpert TB-positive cartridges. 
MTBDRplus had high rates of non-actionable (TUB-band negative or TUB-band positive but indeterminate) and 
false RIF-heteroresistant results (Figs 2 and 3).
In contrast, MTBDRsl on CE had high sensitivity and specificity [87% (47/54) and 100% (9/9) respectively] 
for M. tuberculosis-complex DNA and a limit of detection of 103 CFU/ml. Susceptibility and resistance to FQs and 
SLIDs were correctly detected for all strains ≥103 CFU/ml, corresponding to CT ≤ 24 (the higher CT range of the 
Xpert “low” semiquantitation category) in all but one sample (one replicate of the MDR-TB strain was indeter-
minate for FQs; Fig. 3). Once non-actionable results were excluded, overall sensitivities and specificities of 87% 
(13/15) and 96% (25/26) for FQ-resistance and 94% (15/16) and 97% (30/31) for SLID-resistance, respectively 
were obtained. When the threshold of ≥103 CFU/ml (CT ≤ 24) was applied, the sensitivity and specificity were 
both 100% (12/12 and 23/23, respectively) for FQs and for SLIDs (12/12 and 24/24, respectively).
Figure 1. Cartridge extract extraction procedure. (a) The arrow indicates the diamond-shaped reaction chamber 
where the PCR amplification takes place and contains cartridge extract with mycobacterial genomic DNA. The 
needle is placed at the top of the diamond and the film is slowly and carefully pierced. (b) The needle is then 
slowly inserted deeper into the pocket and cartridge extract mix drawn out without piercing the other side.
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Diagnostic accuracy of MTBDRplus and MTBDRsl on clinical specimen Xpert TB-positve car-
tridge extract. Xpert MTB/RIF rifampicin-susceptible specimens. As with the dilution series, MTBDRplus 
had high rates of indeterminate and false-resistance results on clinical specimen CE (Table 2). However, most 
MTBDRsl results from Xpert TB-positive, RIF-susceptible clinical specimen CE were valid (TUB-positive, not 
indeterminate, and no false-susceptible or -resistant results): 53/56 (95%) for FQ (two TUB-band negative, one 
indeterminate) and 51/56 (91%) for SLID (two TUB-band negative, three indeterminate). The few CEs that 
yielded indeterminate MTBDRsl results corresponded to “low” or “very low” Xpert semiquantitation levels 
(CT > 24). The median (IQR) CT of indeterminate (26.3, 24.4–26.7) vs. determinate (17.62, 15.6–20.6) MTBDRsl 
results differed (p < 0.001), indicating that indeterminate results are likely a function of low DNA concentrations 
in CE. There was not enough CE volume remaining or a matching clinical isolate for confirmatory testing from 
the three MTBDRsl-detected SLIDs resistant patients.
Xpert MTB/RIF rifampicin-resistant specimens. MTBDRsl on Xpert TB-positive, RIF-resistant CE had 24/29 
(83%) valid results. For FQs, 14/24 (58%) were susceptible and 10/24 (42%) were resistant. For SLIDs, 15/24 
(63%) were susceptible and 9/24 (37%) resistant. The five non-valid results were TUB-band-negative [2/29 (7%)] 
or indeterminate for both FQs and SLIDs [3/29 (10%); Table 2]. All CEs corresponding to the higher CT ranges 
of the Xpert “low” semiquantitation category (CT ≤ 24) had valid results, whereas those that had indeterminate 
or TUB band-negative results corresponded to the lower semiquantitation levels (CT > 25.0). The median (IQR) 
CT of indeterminate (29.1, 26.5-31.1) vs. determinate (20.5, 16.−23.2) results differed significantly (p < 0.001).
MTBDRplus and MTBDRsl performance on Xpert MTB/RIF cartridge extract by smear status. MTBDRplus had 
high non-valid result rates irrespective of smear status. However, MTBDRsl on CE from smear-negative spu-
tums had significantly higher rates of non-actionable results [5/23 (22%) vs. 1/43 (2%) for FQ, p = 0.01; 6/23 
(23%) vs. 2/43 (5%) for SLIDs, p = 0.01] compared to smear-positive patients (Supplementary Table 2).
Concordance of MTBDRsl results on cartridge extract and culture isolates. Of the 29 Xpert TB-positive, 
RIF-resistant patients, 20 (69%) matched culture isolates were collected while the remaining nine had negative or 
contaminated cultures. The CEs and isolates showed 18/20 (90%) matching MTBDRsl FQ results and 17/20 (84%) 
matching SLID results. There were 2/20 (10%) discordant TUB-band MTBDRsl results on culture isolates (one 
TUB-positive and FQ and SLID sensitive, one TUB-positive and FQ and SLID resistant) where both CE results 
were TUB-band negative. There was also 1/20 (5%) discordant SLID result (CE showed resistance but the isolate 
showed susceptibility). Importantly, all three discordant results corresponded to a “very low” semiquantitation 
(CT > 28.0). All TUB-band, susceptibility and resistance calls were concordant at CT ≤ 24, indicating that the 
diagnostic accuracy of MTBDRsl on CE vs. isolates is likely comparable at this threshold.
Spoligotyping on cartridge extract. Dilution series. Spoligotyping resulted in a readable strain type for 
dilutions ≥103 CFU/ml, corresponding to the same threshold seen for MTBDRsl.
Clinical specimens. Spoligotyping on specimen CE and crude DNA from matched culture isolates were highly 
concordant 10/10 (100%) at the threshold defined by the dilution series (Table 3). A variety of strain families were 
observed with Beijing as the predominant family type [6/10 (60%)] as well as 2/10 (20%) LAM and 2/10 (20%) 
T1 family type.
Targeted sequencing on extract from used Xpert MTB/RIF cartridges. Dilution Series. Targeted 
Sanger sequencing was done on dilution series CE. For the rrs PCR on CE, sequence shorter than the expected 
length was observed. PCR of gyrA from CE from dilutions 103–104 CFU/ml resulted in sequence expected length, 
however high background noise occurred and the sequence did not align to H37Rv [NC_000962]. gyrA on CE 
from dilutions 105–106 CFU/ml aligned to the reference genome, however, several SNPs known to be present in 
the resistance determining regions (identified by sequencing of the corresponding isolate) were not detected. Due 
to the relatively poor limit of detection and accuracy of Sanger sequencing on dilution series CE, we did not do 
sequencing on clinical specimen CEs.
Patient Characteristics
Xpert TB-positive
Xpert rifampicin-
susceptible (n = 56)
Xpert rifampicin - 
resistant (n = 29)
Age, median (IQR) 40 (30–49) 35 (23–42; p = 0.086)
Male gender (%) 37/55 (67)* 12/20 (60)*
Smear-positivity (%) 37/50 (74)* 6/16 (38)*
Culture-positivity (%) Not done 19/21 (90)*
 TTP, median (IQR) N/A 10 (8–20)
Xpert CT, median IQR 17.9 (16.3–22.1) 20.5 (16.9–24.8)
Table 1. Patient demographic and clinical data. *Missing data: Gender (n = 1 for RIF-susceptible, n = 9 for RIF-
resistant); Smear status (n = 6 for Xpert RIF susceptible, n = 13 for Xpert RIF-resistant); Culture results (n = 8 
for RIF-resistant results). Abbreviations: Xpert - Xpert MTB/RIF; IQR - interquartile range; TTP - time-to-
positivity; CT - cycle threshold values.
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Figure 2. Results of MTBDRplus and MTBDRsl on Xpert CE from a dilution series of DS-, MDR- and 
XDR-TB strains. MTBDRplus (irrespective of concentration and strain) had high TUB-band negativity and 
indeterminate rates. However, MTBDRsl had high sensitivity and specificity and low indeterminate rates. For 
each dilution, left bars are for rifampicin (MTBDRplus, top row) or fluoroquinolones (MTBDRsl, bottom row) 
and right bars are for isoniazid (MTBDRplus) or second-line injectables (MTBDRsl). Data from LPA on DS-TB, 
MDR-TB and XDR-TB strains are shown. The experiment was done in triplicate. Abbreviations: CFU – colony 
forming; DS-TB – drug susceptible TB; MDR-TB – multidrug resistant TB; XDR-TB – extensively drug resistant 
TB; units; Xpert - Xpert MTB/RIF.
Figure 3. Xpert MTB/RIF quantitative information [average cycle threshold (CT) values] (line graph, right 
y-axes) versus bacterial load (CFU/ml) in a triplicate dilution series for MTBDRplus (a) and MTBDRsl 
(b) done on CE. Left y-axes (bars) show the proportion of assays with non-valid results, disaggregated into 
non-actionable (TUB-band negative, indeterminate) and non-valid (false-susceptible, false-resistant). For 
each dilution, left bars are for rifampicin (MTBDRplus, top) or fluoroquinolones (MTBDRsl, bottom) and 
right bars are for isoniazid (MTBDRplus) or second-line injectables (MTBDRsl). Beyond 103 CFU/ml, there 
were no false resistance or susceptibility calls for MTBDRsl, which corresponds to CT ≤ 24. CT ≥ 38 (horizontal 
dashed line) correspond to a negative Xpert. Error bars show standard error (SE) of average CT. Right y-axes 
show CT corresponding to Xpert semiquantitation levels of very low (CT > 28), low (CT = 22–28), medium 
(CT = 16–22) and high (CT < 16). Pooled data from LPAs on DS-TB, MDR-TB and XDR-TB strains are 
shown. Abbreviations: CFU – colony forming; DS-TB – drug susceptible TB; MDR-TB – multidrug resistant 
TB; XDR-TB – extensively drug resistant TB; CFU – colony forming units; Xpert - Xpert MTB/RIF.
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All Xpert TB-positive specimens Xpert TB-positive specimens with CT ≤ 24
Xpert rifampicin-susceptible Xpert rifampicin-resistant Xpert rifampicin-susceptible Xpert rifampicin-resistant
MTBDRplus (n = 56) MTBDRsl (n = 56) MTBDRsl (n = 29)* MTBDRplus (n = 49) MTBDRsl (n = 49) MTBDRsl (n = 20)*
TUB-band positive (%) 
47/56 (84)
TUB-band positive (%) 
47/54 (96)
TUB-band positive (%) 
27/29 (93)
TUB-band positive (%) 
45/49 (92)
TUB-band positive (%) 
49/49 (100)
TUB-band positive (%) 
20/20 (100)
Rifampicin (%) Fluoroquinolones (%) Fluoroquinolones (%) Rifampicin (%) Fluoroquinolones (%) Fluoroquinolones (%)
Susceptible 0/47 (0) Susceptible 53/54 (98) Susceptible 14/27 (52) Susceptible 0/56 (0) Susceptible 49/49 (100) Susceptible 11/20 (55)
Resistant 47/47 (100) Resistant 0/54 (0) Resistant 10/27 (37) Resistant 45/49 (92) Resistant 0/49 (0) Resistant 9/20 (45)
Indeterminate 0/47 (0) Indeterminate 1/54 (2) Indeterminate 3/27 (11) Indeterminate 0/49 (0) Indeterminate 0/49 (0) Indeterminate 0/20 (0)
Isoniazid (%) Second-line injectables %) Second-line injectables (%) Isoniazid (%) Second-line injectables (%) Second-line injectables (%)
Susceptible 11/47 (23) Susceptible 48/54 (88) Susceptible 15/27 (56) Susceptible 11/49 (23) Susceptible 46/49 (94) Susceptible 14/20 (70)
Resistant 0/47 (0) Resistant 3/54 (6) Resistant 9/27 (33) Resistant 0/49 (0) Resistant 1/49 (2) Resistant 6/20 (30)
Indeterminate 36/47 (77) Indeterminate 3/54 (6) Indeterminate 3/27 (11) Indeterminate 34/49 (69) Indeterminate 2/49 (4) Indeterminate 0/20 (0)
TUB-band negative (%) 
9/56 (16)
TUB-band negative (%) 
2/56 (4)
TUB-band negative (%) 
2/29 (7)
TUB-band negative (%) 
4/49 (8)
TUB-band negative (%) 
0/49 (0)
TUB-band negative (%) 
0/20 (0)
Table 2. Results of MTBDRplus and MTBDRsl drug susceptibility testing using cartridge extract on clinical 
specimens. MTBDRplus had high indeterminate results and rifampicin-resistance false-positive rates. MTBDRsl 
had low indeterminate rates for both DS-TB and DR-TB specimens and performance improved when MTBDRsl 
was done only on specimens with CT ≤ 24. *For the 29 Xpert RIF-resistant specimens we were able to retrieve 
20 paired culture isolates used for MTBDRsl. 18/20 matched for FQs and 17/20 for SLIDs, the 2/20 done 
on crude DNA had LPA results whereas the LPA on CE was TUB-band negative. 1/20 did not match for the 
SLID resistance. Both the TUB-band negative and discordant SLIDs result corresponded to “very low” semi-
quantitation level. When defined threshold of CT ≤ 24 was applied all LPAs on CE matched LPA from culture 
isolates.
Table 3. Spoligotyping results performed on CE done on sputum specimens and paired culture isolates at 
defined threshold (CT ≤ 24).
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Discussion
Our key findings are: (1) MTBDRsl on CE enabled genotypic drug-susceptibility testing for FQs and SLIDs with 
high accuracy and low indeterminate rates when the Xpert semiquantitation category was at least “medium” or 
CT ≤ 24 (corresponding to ≥ 103 CFU/ml), (2) spoligotyping was feasible and accurate on CE at the same thresh-
old, (3) MTBDRplus was not feasible or accurate on CE and (4) neither was Sanger sequencing. These data have 
implications for the routine diagnosis of drug-resistant TB, researchers, and test developers.
Xpert is one of the most widely used tests for TB and drug-resistance9,34 and although it is a significant 
advancement, time-to-treatment – especially for MDR- and XDR-TB - is still very long35–38. Our results show 
that accurate second-line drug testing using MTBDRsl is possible on CE from Xpert cartridges that would oth-
erwise be discarded. This potentially allows for a rapid, single-specimen diagnosis of XDR-TB without addi-
tional specimen collection. Importantly, we defined a threshold at which this approach is feasible, meaning that 
MTBDRsl assays do not need to be wasted on CE unlikely to give a valid result. Using this threshold, we showed 
that on clinical specimen CEs, susceptibility and resistance calls were concordant with those from the isolate19,39. 
Furthermore, we showed that it is possible to do spoligotyping on CE at this threshold, which will inform strain 
surveillance and research studies on relapse and reinfection where specimens are limited. Collectively, these find-
ings may reduce the need for culture.
Although our data suggest that the MTBDRsl will work on CE from cartridges with an Xpert semiquantita-
tion category of at least “low”, we suggest that, in laboratories where CT cannot be readily calculated, a category 
of at least “medium” is used to guide use of this strategy unless the laboratory is comfortable with some sem-
iquantitation low specimens not having a valid MTBDRsl result. Alternatively, if smear microscopy is availa-
ble, smear-positivity may be used to guide use of CE, however, some smear-negative specimens in whom this 
approach would work (103-104 CFU/ml) would be unnecessarily excluded.
When considering the CE approach, it is important to identify a safe and sterile environment to avoid con-
tamination. Although Xpert sample reagent as well as the sonication lysis step within the cartridge helps ensure 
M. tuberculosis is no longer culturable (and therefore poses minimal infectious risk40), steps to minimise the risk 
of rpoB amplicon cross-contamination should be implemented. These can include working in a dedicated cabi-
net or room and sterilising the work area with UV and disinfectant after CE is collected. Importantly, however, 
cross-contamination of other Xpert cartridges with rpoB amplicons appears unlikely. Although Xpert’s automated 
pre-amplification wash step does not remove large pieces of debris-associated genomic DNA, it does efficiently 
remove high concentrations of contaminating rpoB amplicons from assays like MTBDRplus41,42. NAATs without 
such a wash step may be more vulnerable to CE rpoB amplicon cross-contamination.
Our study differed from a previous study which showed that sequencing, MTBDRplus, spoligotyping and 
MIRU-VNTR typing are feasible on the sputum mixed with Xpert sample reagent43. However, this sample 
reagent method has a number of disadvantages: 1) often no volume remains, 2) prolonged exposure to sample 
reagent degrades DNA and potentially introduces mutations9,40, and 3) it still requires DNA extraction prior 
to PCR. Furthermore, DNA extraction adds cost and is not always feasible in laboratories in high burden 
countries; whereas the CE method yields directly usable material and does not need additional extraction 
or purification steps. An advantage, however, of using the sputum mixed with Xpert reagent buffer, is that 
it likely avoids high MTBDRplus error rates (TUB-band negative, indeterminate, false-positive) seen with 
CE. This could be due to the large amount of rpoB amplicons in Xpert TB-positive CE, which share bind-
ing sites with MTBDRplus probes and confound the assay resulting in non-valid results. Furthermore, the 
rpoB PCR that occurs as part of MTBDRplus may sequester reagents away from the multiplex inhA and katG 
amplification reactions. Testing for mutations conferring INH resistance using CE might hence be possible 
with the Genoscholar INH II line probe assay (which does not contain rpoB probes)44. Sequencing from CE 
thus primarily appears to be driven by rpoB amplicon interference (although a PCR clean-up was done prior 
to sequencing, this would have co-purified rpoB amplicons). Further investigation with primers optimised for 
minimal-input DNA may be warranted, however, it appears that, for sequencing, the best approach to avoid 
contaminating amplicons might be to PCR from the specimen-Xpert sample reagent mixture43. Given the rates 
of non-valid CE results below the defined threshold, we suggest that specimen-Xpert sample reagent mix be 
kept in the event that CT falls >24. 
The results presented here should be interpreted in context of their limitations. For the clinical specimens 
tested from the NHLS, matched culture isolates were not available for Xpert RIF-susceptible specimens, as 
per the national algorithm. However, the dilution series experiments showed very high concordance between 
MTBDRsl on CE vs. the isolates. The utility of CE depends on the downstream test used and MTBDRsl sus-
ceptible or non-valid results should be interpreted from CE the same as when they are done on patient spec-
imens (i.e., further investigation, including culture, is recommended)45. Realistically, cartridges may need to 
be transported from remote locations and so the effect of storing cartridges for prolonged duration (>5 days) 
and at ambient temperature requires further systematic testing. Using bacilli in buffer can have limitations, 
which is why we also used patient clinical specimens, which are a better material to test than bacilli added to 
sputum (the former has bacilli within a sputum matrix, whereas in the latter bacilli are typically freely floating 
in bubbles). 
In conclusion, CE contains template DNA for second-line DST using MTBDRsl, resulting in accurate results 
highly concordant with those from isolates, provided bacillary load in the specimen corresponds to at least a 
“medium” Xpert semiquantitation category of CT ≤ 24. This potentially facilitates XDR-TB detection within days 
from a single specimen. Spoligotyping is also feasible on CE and works consistently at this threshold. Our method 
provides an opportunity to potentially reduce the burden associated with addition specimen collection, such as 
patient treatment delay, pre-treatment loss-to-follow-up, and increased patient and provider costs. Furthermore, 
it shows that material that would otherwise be discarded still holds diagnostic utility.
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